Pular para o conteúdo principal
Ranking Invest

SRRK - Scholar Rock Holding Corporation

Segmento: HealthcareScholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Análise Ranking Invest

Valuation estimado
-$ 734.45 Mi
Valor de Mercado
$ 6.74 Bi
Desconto (AV)-1017.6%
IVR
-0.11A companhia vale -0,11 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.15O valuation alternativo equivale a -15% do valor de mercado da companhia.
MLL
-0.15O lucro líquido dos controladores em 16 trimestres equivale a -15% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 253.78 Mi

Dívida Líquida

-$ 240.89 Mi

L4T

-$ 408.59 Mi

Indicadores Básicos

ROE

-161.00%

Índices de Previsibilidade

Receita Líquida

G1.54

Lucro

A0.13

Margem

E1.21

Índices de Tendência

Receita Líquida

D-2.38

Lucro

G-11.16

Margem

B4.74

Índices de Endividamento

DIV/PAT

-0.95

DIV/L4T

0.59

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.